Medigene, the German biotech focused on immunotherapy to treat cancer, has named Pamela Keck as its vice president and head of IR and corporate communications.
Most recently, Keck worked as vice president of corporate communications and IR at neurocare group, another German healthcare company.
Between 2018 and 2022, she was head of IR at Biofrontera, which focuses on skin treatments. During this time, she supported a spin-off IPO on Nasdaq.
Keck has also held IR and communications roles at a range of other companies, including Information Services Corporation.
‘Pamela’s extensive investor relations experience in the biotech industry and wealth of financial expertise will be invaluable as we execute our updated growth strategy and pipeline expansion,’ says Selwyn Ho, CEO of Medigene, in a statement.
‘We are delighted to have her join us and we look forward to her leadership for our investor relations and corporate communications initiatives.’
Keck adds: ‘I’m honored to join the Medigene team and look forward to engaging with the investor community and helping deliver value for all our stakeholders.’